This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Mirati (MRTX) Seeks EU Nod for Adagrasib to Treat Lung Cancer
by Zacks Equity Research
Mirati (MRTX) seeks a nod for its lung cancer candidate adagrasib in the European Union. A regulatory filing in the United States is currently under the FDA review with decision pending this year-end.
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck, and Glaxo
by Zacks Equity Research
Eli Lilly, Novo Nordisk, Merck, and Glaxo are part of Zacks Industry Outlook article.
4 Large Drug Stocks to Watch as the Industry Recovers
by Kinjel Shah
Drug/biotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Glaxo (GSK) are worth retaining in your portfolio.
Merck (MRK) Outperforms Industry This Year So Far: Here's Why
by Zacks Equity Research
Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and positive pipeline/regulatory developments have been keeping Merck's (MRK) stock afloat in 2022.
Pfizer (PFE) Gets EUA for Use of Comirnaty Booster in Children
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech gets authorization for emergency use of booster dose of its COVID-19 vaccine, Comirnaty, in children aged between 5 years and 11 years.
Bristol Myers (BMY) Phase III CheckMate -901 Study Disappoints
by Zacks Equity Research
Bristol Myers (BMY) phase III CheckMate -901 study fails to meet the primary endpoint of overall survival in patients with untreated unresectable or metastatic urothelial cancer.
Exelixis (EXEL) Q1 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Exelixis (EXEL) beats on earnings but misses on revenues in the first quarter. While the top line increases on a year-over-year basis, the bottom line improves from the year-ago breakeven figure.
Top Analyst Reports for Comcast, CME & Charter Communications
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Comcast Corporation (CMCSA), CME Group Inc. (CME), and Charter Communications, Inc. (CHTR).
Corcept's (CORT) Q1 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Corcept's (CORT) earnings as well as revenues miss estimates in the first quarter of 2022.
Iovance (IOVA) Q1 Earnings Beat, Lifileucel BLA on Track
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) reports a narrower-than-expected first-quarter loss. The company is on track to file a regulatory submission for lifileucel in melanoma in August 2022.
Why Merck (MRK) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Mirati (MRTX) Q1 Loss Wider Than Expected, Sales Beat
by Zacks Equity Research
Mirati Therapeutics (MRTX) reports wider-than-expected Q1 loss while revenues beat the mark. MRTX plans to enter two new candidates into early-stage clinical studies in second-half 2022.
Moderna (MRNA) Beats on Q1 Earnings, to Start Two Late Studies
by Zacks Equity Research
Moderna's (MRNA) Spikevax sales beat expectations. The company plans to start late-stage studies for Omicron-containing bivalent booster and seasonal flu vaccines later this year. Stock gains in pre-market.
Is a Beat Likely for Moderna (MRNA) This Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the first-quarter earnings call that can help it to reduce its dependence on Spikevax.
AstraZeneca (AZN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AstraZeneca's (AZN) first-quarter results reflect a beat on both counts (revenues and earnings). AZN maintains its 2022 guidance.
Seagen's (SGEN) Q1 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Seagen (SGEN) reports narrower-than-expected loss in the first quarter of 2022 while its revenues beat estimates.
Pharma Stock Roundup: Q1 Earnings of LLY, MRK & NVS, FDA Updates for AZN & PFE
by Kinjel Shah
Eli Lilly (LLY), Merck (MRK), Novartis (NVS) and others announce Q1 results. FDA updates for AstraZeneca (AZN) and Pfizer (PFE) grab headlines in the pharma space.
Company News for Apr 29, 2022
by Zacks Equity Research
Companies In The News Are: TWTR, PYPL, MRK, MCD.
Alkermes (ALKS) Q1 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Alkermes (ALKS) rides high on both earnings and sales beating estimates in the first quarter of 2022.
Merck (MRK) Q1 Earnings & Sales Beat, COVID Drug Adds $3.3B
by Zacks Equity Research
Merck (MRK) beats Q1 estimates for earnings and sales. The company anticipates robust growth in revenues and income to continue in 2022.
Merck (MRK) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 18.23% and 5.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks Q1 Earnings Due on Apr 28: MRK, LLY & More
by Zacks Equity Research
Let us look at the five biotech/pharma companies, slated to release quarterly results on Apr 28.
Why Earnings Season Could Be Great for Merck (MRK)
by Zacks Equity Research
Merck (MRK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
The Zacks Analyst Blog Highlights Novo Nordisk, Advanced Micro Devices, Netflix, Merck, and Marsh & McLennan
by Zacks Equity Research
Novo Nordisk, Advanced Micro Devices, Netflix, Merck, and Marsh & McLennan have been included in this Analyst Blog.
Top Research Reports for Novo Nordisk, AMD & Netflix
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Advanced Micro Devices, Inc. (AMD), and Netflix, Inc. (NFLX).